H.R. 6963 117th Congress
Accelerated Approval Integrity Act of 2022
- Health
- Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6]
- Congress.gov ↗
Latest action, Mar 8, 2022: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
1 cosponsor
Sponsored by Rep. Pallone, Frank, Jr. [D-NJ-6] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
1 D · 0 R
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMERIHEALTH CARITAS
GREENBERG TRAURIG, LLP
4 reports
4 reports
4 reports
BIOMARIN PHARMACEUTICAL INC.
CHAMBER HILL STRATEGIES
4 reports
4 reports
4 reports
4 reports
HARMONY BIOSCIENCES, LLC
RAMPY NORTHRUP LLC
4 reports
4 reports
4 reports
4 reports
4 reports
All 25 of 31 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERIHEALTH CARITAS | GREENBERG TRAURIG, LLP | 4 | $120K | Q1 2022 | Q3 2022 | yes |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 4 | $3.2M | Q1 2022 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 4 | $4.8M | Q1 2022 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | CHAMBER HILL STRATEGIES | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $13.3M | Q1 2022 | Q3 2022 | yes | |
| EMD SERONO INC | 4 | $2.2M | Q1 2022 | Q3 2022 | yes | |
| GENENTECH INC | 4 | $8.8M | Q1 2022 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 4 | $4.5M | Q1 2022 | Q3 2022 | yes | |
| HARMONY BIOSCIENCES, LLC | RAMPY NORTHRUP LLC | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) | 4 | $5.0M | Q1 2022 | Q3 2022 | yes | |
| INOVIO PHARMACEUTICALS, INC. | 4 | $560K | Q1 2022 | Q3 2022 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 4 | $5.7M | Q1 2022 | Q3 2022 | yes | |
| MERCK & CO INC | 4 | $8.3M | Q1 2022 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 4 | $28.3M | Q1 2022 | Q3 2022 | yes | |
| REGENXBIO | 4 | $372K | Q1 2022 | Q3 2022 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | $4.9M | Q1 2022 | Q3 2022 | yes | |
| TEVA PHARMACEUTICALS USA INC | 4 | $3.9M | Q1 2022 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | 4 | $810K | Q1 2022 | Q3 2022 | yes | |
| AMGEN INC | 3 | $8.0M | Q1 2022 | Q3 2022 | yes | |
| BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) | 3 | $260K | Q4 2022 | Q3 2022 | yes | |
| HARMONY BIOSCIENCES | 3 | $750K | Q4 2022 | Q3 2022 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 3 | $5.9M | Q4 2022 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 3 | $0 | Q4 2022 | Q3 2022 | yes |
| BIOMARIN PHARMACEUTICAL INC. | 2 | $780K | Q1 2022 | Q2 2022 | yes | |
| CHIESI USA, INC. | THE KPM GROUP DC LLC | 2 | $0 | Q1 2022 | Q2 2022 | yes |